Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En öppen förlängningsstudie av ORKA-001 hos deltagare med plackpsoriasis

21 oktober 2026 uppdaterad av: Oruka Therapeutics, Inc.

En öppen förlängningsstudie för att utvärdera långtids säkerhet, tolerabilitet och effekt av ORKA-001 hos deltagare med måttlig till svår plackpsoriasis

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.

Studietyp

Interventionell

Inskrivning (Beräknad)

240

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85032
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Arkansas
      • North Little Rock, Arkansas, Förenta staterna, 72117
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • California
      • Fountain Valley, California, Förenta staterna, 92708
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Los Angeles, California, Förenta staterna, 90045
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Los Angeles, California, Förenta staterna, 90095
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • San Diego, California, Förenta staterna, 92123
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Santa Ana, California, Förenta staterna, 92701
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Santa Monica, California, Förenta staterna, 90403
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Connecticut
      • Cromwell, Connecticut, Förenta staterna, 06416
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Florida
      • Miami, Florida, Förenta staterna, 33126
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Illinois
      • Rolling Meadows, Illinois, Förenta staterna, 60008
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Indiana
      • Plainfield, Indiana, Förenta staterna, 46168
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Kentucky
      • Bowling Green, Kentucky, Förenta staterna, 42104
    • Maryland
      • Rockville, Maryland, Förenta staterna, 20850
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02111
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48202
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • New York
      • New York, New York, Förenta staterna, 10023
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • New York, New York, Förenta staterna, 10029
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Mason, Ohio, Förenta staterna, 45040
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Oregon
      • Portland, Oregon, Förenta staterna, 97201
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Portland, Oregon, Förenta staterna, 97210
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Texas
      • Frisco, Texas, Förenta staterna, 75033
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Houston, Texas, Förenta staterna, 77004
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Webster, Texas, Förenta staterna, 77598
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Virginia
      • Norfolk, Virginia, Förenta staterna, 23502
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Alberta
      • Edmonton, Alberta, Kanada, T5J 3S9
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Edmonton, Alberta, Kanada, T6G 1C3
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • British Columbia
      • Surrey, British Columbia, Kanada, V3R 6A7
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Surrey, British Columbia, Kanada, V3V 0C6
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • New Brunswick
      • Fredericton, New Brunswick, Kanada, E3B IG9
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Ontario
      • Ajax, Ontario, Kanada, L1S7K8
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • London, Ontario, Kanada, N6H 5L5
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Markham, Ontario, Kanada, L3P 1X3
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Peterborough, Ontario, Kanada, K9J 5K2
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Toronto, Ontario, Kanada, M4W 2N4
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Waterloo, Ontario, Kanada, N2J 1C4
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Kanada, H2X2V1
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:
      • Québec, Quebec, Kanada, G1V4X7
        • Rekrytering
        • Oruka Therapeutics Investigative Site
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Signed informed consent by participants from previous trial choosing to transition into the OLE.
  2. Participants who have successfully completed the preceding trial.
  3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
  4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception

Exclusion Criteria:

  1. Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
  2. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
  3. Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
  4. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
  5. Participant is pregnant or breastfeeding.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: ORKA-001 Once Yearly (High Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Experimentell: ORKA-001 Once Yearly (Low Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Experimentell: ORKA-001 Twice Yearly

Participants will receive ORKA-001 every 6 months per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

Inget ingripande: No Drug

Participants will receive no drug until protocol defined PASI response criterion is met.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Tidsram: Day 1 through Week 144

Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.

Day 1 through Week 144

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsram: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsram: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsram: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsram: Time Frame: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Time Frame: Day 1 through Week 96
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Tidsram: Day 1 through Week 96

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Tidsram: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Tidsram: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
PASI Score Over Time
Tidsram: Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
IGA Score Over Time
Tidsram: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 februari 2026

Primärt slutförande (Beräknad)

1 maj 2030

Avslutad studie (Beräknad)

1 juli 2030

Studieregistreringsdatum

Först inskickad

26 februari 2026

Först inskickad som uppfyllde QC-kriterierna

26 februari 2026

Första postat (Faktisk)

4 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 oktober 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • ORKA-001-113

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera